Citadel Advisors
SVNT

Citadel Advisors’s SAVIENT PHARMACEUTICALS INC SVNT Stock Holding History

Citadel Advisors’s Portfolio SVNT Stock Details SVNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-29,400
Closed -$18K – 7467
2013
Q3 		$18K Buy
29,400
+16,400
+126% +$10.5K ﹤0.01% 6292
2013
Q2 		$7K Buy
+13,000
New +$9.06K ﹤0.01% 6322

Other funds holding SVNT

Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
FHC
First Heartland Consultants Lake St. Louis, Missouri $1.55B AUM 20.5% 1-Year Est. Return
PSC
Prentiss Smith & Co Brattleboro, Vermont $172M AUM 21.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Citadel Advisors's SVNT Position: Q4 2013 in Review

Citadel Advisors sold out of SAVIENT PHARMACEUTICALS INC (SVNT) in Q4 2013, closing a stake of 31,407 shares — an estimated $20K sold.

Citadel Advisors first reported a position in SVNT in Q2 2013 and held it in 2 quarters. The position peaked at $42K in Q2 2013. 7 funds tracked by Wall St. Rank hold SVNT as of Q4 2013.

  • Citadel Advisors reported no remaining SAVIENT PHARMACEUTICALS INC position as of Q4 2013 after selling out during the quarter.
  • Citadel Advisors sold 31,407 SAVIENT PHARMACEUTICALS INC shares in Q4 2013, an estimated $20K.
  • Citadel Advisors first reported a position in SAVIENT PHARMACEUTICALS INC in Q2 2013 and held it in 2 quarters.
  • Citadel Advisors's SAVIENT PHARMACEUTICALS INC position peaked at $42K in Q2 2013.
  • 7 funds tracked by Wall St. Rank held SAVIENT PHARMACEUTICALS INC as of Q4 2013.

Based on Citadel Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.